Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
RegeneRx Biopharmaceuticals, Inc.
Biopharma company announces net loss of $0.10 per share for the year
April 26th, 2005
RegeneRx Biopharmaceuticals, Inc., (RGN) announced the results of its year ended December 31, 2004. The company had a net loss of $3,326,399 or $0.10 per share for the year ended December 31, 2004, compared with net loss of $1,659,875 or $0.06 per share for the year ended December 31, 2003. The net loss for 2004 resulted primarily from the continued research and development expenditures related to the initiation of phase II clinical trials to study the company's product, Thymosin beta 4 (TB4) for the treatment of chronic dermal wounds, research and development efforts related to its technology, scale-up manufacturing and formulation efforts, and the administrative costs...
Source: Cardiovascular Business Week (2005-04-26)
|
